Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Elimination of [14C]E2027 in Healthy Male Subjects
NCT04023877Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Irsenontrine in dementia with Lewy bodies (DLB), sponsored by Eisai Co., Ltd. Primary endpoints: Cumulative Percent of the Radiolabeled Dose of [14C]E2027 in Biological Matrices up to 56 days, Maximum Concentration of Radiolabeled [14C]E2027, Non-Radiolabeled E2027 and Metabolites and 8 more. Started Jul 2019; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT04023877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023877.